| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | petosemtamab Combination with pembrolizumab | Phase 3 | — | Biologics | Oncology | ||
Phase 3 topline data readout example | petosemtamab Combination with pembrolizumab | Phase 3 | — | Biologics | Oncology | ||
Phase 3 topline data readout example | petosemtamab Combination with pembrolizumab | Phase 3 | — | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Merus N.V.$90
-6.86 (-7.08%)
C 46Pipeline Score Overvalued Biotech · Clinical
Market Cap
6.83 B
EPS
-5.33
P/E Ratio
-
Value Trade
252.72 M
-7.12 %
Week
-6.35 %
1 Month
-3.87 %
3 Month
71.33 %
6 Month
418.73 %
5 Year
823.08 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
2.73 M
52 Week Range
33.19 - 97.14
% held by Insiders
10.96 %
% held by Institutions
90.07 %
Enterprise Value
6.20 B
Total Shares
75.63 M
Short %
1.17 %
Float Shares
69.95 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C46
Pipeline Score $1.8B
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.3x
rNPV / MCap Top 70%
Small Cap (rank 272 of 905)
Percentile RankMerus N.V. carries a moderate pipeline score (46/100), with $2.8B risk-adjusted pipeline value, led by Petosemtamab in Head and Neck Squamous Cell Carcinoma (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Petosemtamab Small molecule | Head and Neck Squamous Cell Carcinoma | Phase 3 | NCT06525220 | 65% | $1.5B | RECRUITING | 1,300 | VERY_FAST | C (57) | Jul 1, 2030 | - | LOW Jun 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Petosemtamab | recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) | Phase 2 | 2025-08-06 | |||
Petosemtamab | recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) | Phase 2 | 2025-08-06 | |||
Petosemtamab | recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) | Phase 2 | 2025-08-06 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MRUS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
MRUS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MRUS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MRUS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
MRUS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
MRUS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How MRUS ranks across every disease it competes inCompetitive Position is a premium feature
See how MRUS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial